Bioprinted Perfusable Multi‐Cellular Liver Model Using Matrix Metalloproteinase ‐Degradable Hydrogel
Open Access
- 20 April 2026
- journal article
- research article
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (47) , e00040
Abstract
Developing predictive human in vitro drug screening platforms requires models that capture the spatial complexity, cellular diversity, and functional maturity of a native liver tissue. Here, we present a bioprinted multi‐cellular liver model that integrates induced pluripotent stem cells (iPSCs)‐derived hepatocytes and endothelial cells within a matrix metalloproteinase (MMP)‐degradable, YIGSR‐functionalized polyethylene glycol (PEG)—norbornene (NB) hydrogel. The multi‐cellular architecture recapitulates hepatic organization by spatially positioning endothelial and parenchymal compartments in physiologically relevant arrangements, enabling paracrine signaling, enhanced nutrient exchange, and stable cell–cell/matrix interactions. Integrated with a dynamic microfluidic perfusion system, the construct supports matrix remodeling, delivers physiological shear stress, and sustains a well‐oxygenated microenvironment. Compared to static culture, dynamic perfusion preserved long‐term albumin and urea secretion, enhanced cytochrome P450 activity, reduced oxidative stress, and maintained mitochondrial integrity over extended culture periods. Transcriptomic profiling confirmed significant enrichment of metabolic, junctional, and drug‐processing pathways. Functionally, the multi‐cellular platform demonstrated robust and inducible drug‐metabolizing capacity, enabling accurate identification of clinically relevant hepatotoxic compounds. Drug potency metrics—including IC 50 and benchmark dose values—closely matched reported human plasma concentration thresholds, underscoring the translational potential of the system. This reproducible, physiomimetic multi‐cellular liver platform provides a high‐content, human‐iPSC based liver tissue to conventional preclinical models, bridging the gap between early‐stage drug testing and clinical outcomes while offering new opportunities for predictive pharmacology and toxicity assessment.Keywords
Funding Information
- National Science Foundation (2135720)
- Advanced Research Projects Agency for Health (D25AC00432‐00)
- Foundation for the National Institutes of Health (R21ES034455)
This publication has 40 references indexed in Scilit:
- hESCs‐derived Organoids Achieve Liver Zonation Features through LSEC ModulationAdvanced Science, 2025
- Bioprinted high cell density liver model with improved hepatic metabolic functionsBiomaterials, 2025
- Microfluidic human physiomimetic liver model as a screening platform for drug induced liver injuryBiomaterials, 2024
- 3D Printing of Succulent‐Inspired Microneedle Array for Enhanced Tissue Adhesion and Controllable Drug ReleaseAdvanced Materials Technologies, 2024
- 3D microperfusion of mesoscale human microphysiological liver models improves functionality and recapitulates hepatic zonationActa Biomaterialia, 2023
- Microfluidic organ-on-a-chip models of human liver tissueActa Biomaterialia, 2020
- Engineering Liver Microtissues for Disease Modeling and Regenerative MedicineAdvanced Functional Materials, 2020
- Controlled Growth Factor Release in 3D‐Printed HydrogelsAdvanced Healthcare Materials, 2019
- Incorporating 4D into Bioprinting: Real‐Time Magnetically Directed Collagen Fiber Alignment for Generating Complex Multilayered TissuesAdvanced Healthcare Materials, 2018
- Drug Metabolism in the LiverClinics in Liver Disease, 2017